Immune Escape in Breast Cancer During <i>In Situ</i> to Invasive Carcinoma TransitionCarlos R. Gil Del Alcazar, Kornélia Polyák, Lina Ding et al.|Cancer Discovery|2017Cited by 242
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancerDaniel G. Stover, Nancy U. Lin, Carlos R. Gil Del Alcazar et al.|npj Breast Cancer|2018Cited by 150
Immune Escape during Breast Tumor ProgressionCarlos R. Gil Del Alcazar, Kornélia Polyák, Maša Alečković|Cancer Immunology Research|2020Cited by 129
Genomic Alterations during the <i>In Situ</i> to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune SystemAnne Trinh, Kornélia Polyák, Carlos R. Gil Del Alcazar et al.|Molecular Cancer Research|2020Cited by 38
Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast CancerCarlos R. Gil Del Alcazar, Kornélia Polyák, Anne Trinh et al.|Cancer Immunology Research|2022Cited by 32